Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Keon Uk Park"'
Autor:
Jin Hyoung Kang, Ho Jung An, Jin Young Kim, Jin Seok Ahn, Joohyuk Sohn, Hwan Jung Yun, Gun Min Kim, Jung Hye Kwon, Dong Hoe Koo, Keon Uk Park, Hunho Song, Young Mi Seol, Hwa Jung Kim, Hyun Woo Lee, Yun-Gyoo Lee, Ji Hyun Yang
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
PurposeThe purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)–induced nausea and vomiting. Materials
Autor:
Jin Hyoung Kang, Si Young Kim, Sang We Kim, Yoon Ho Ko, Na-Ri Lee, Hwa Jung Kim, Hyo Jung Kim, Hwan Jung Yun, Hyun Woo Lee, Keon Uk Park, Jin Seok Ahn, Eun Kee Song, Soon Nam Lee, S Shin, Yo Han Cho, Joung Soon Jang, Se Ryeon Lee, Jun Suk Kim, Yang Soo Kim
Publikováno v:
The Oncologist. 20:1440-1447
Background. A combination of serotonin receptor (5-hydroxytryptamine receptor type 3) antagonists, NK-1 receptor antagonist, and steroid improves the complete response (CR) of chemotherapy-induced nausea and vomiting (CINV) in cancer patients. Ramose
Autor:
Hyeong Ju Kwon, Yoon Woo Koh, Byung Woog Kang, Eun Chang Choi, Ji Hyun Lee, Min Goo Lee, Se Hun Kim, Se-Hoon Lee, Myung-Ju Ahn, Joo Hang Kim, Mi Ran Yun, Tae Min Kim, Jin Hee Sohn, Hye Ryun Kim, Soonmyung Paik, Sung Bae Kim, Keon Uk Park, Inkyung Jung, Dong Hoe Koo, Nak Jung Kwon, Bomi Kim, Hwan Jung Yun, Dok Hyun Yoon, Han Sang Kim, Byoung Chul Cho, Jong Mu Sun
Publikováno v:
Clinical Cancer Research. 21:544-552
Purpose: The goals of this study were to investigate the clinical activity, safety, and biomarkers of dacomitinib, an irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4, in recurrent and/or metastatic squamous cell carcinoma of the head a
Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer
Autor:
Jin Ho Baek, Yee Soo Chae, Byung Woog Kang, Jin Young Kim, Min Kyoung Kim, Kyung Hee Lee, Hong Suk Song, Keon-Uk Park, Sung Hwa Bae, Yoon Young Cho, Jong Gwang Kim, Young Rok Do, Hun Mo Ryoo
Publikováno v:
Anticancer research. 37(3)
This multicenter phase II clinical trial was designed to evaluate the efficacy and safety of weekly Genexol-PM® and gemcitabine combination chemotherapy in patients with unresectable or metastatic biliary tract cancer. Patients and methods Patients
Autor:
Jung Hye Kwon, Boram Han, Jung Han Kim, Hun Ho Song, Ho Young Kim, Dae Young Zang, Joo Young Jung, Keon Uk Park, Hyo Jung Kim, Dae Ro Choi, Hyeong Su Kim, Geundoo Jang
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
PURPOSE Combination therapy with aprepitant, serotonin receptor antagonist, and steroids improves the complete response rate of both acute and delayed chemotherapy-induced nausea and vomiting (CINV). However, it is not known whether ramosetron is sui
Autor:
Hyo Jeong Yun, Joonghyun Ahn, Jung Hye Kwon, Hyunna Lee, Y. Lee, J. H. Kang, Joohyuk Sohn, Y.M. Seol, H.J. An, Keon Uk Park, Hyunyong Kim
Publikováno v:
Annals of Oncology. 29:viii610
Autor:
Joo Hang Kim, Yoon Woo Koh, Patrick Tan, John R. McPherson, Sangwoo Kim, Han Sang Kim, Eun Chang Choi, Kie Kyon Huang, Hyeong Ju Kwon, Kang Won Jang, Hye Ryun Kim, Kalpana Ramnarayanan, Bin Tean Teh, Steven G. Rozen, Kakoli Das, Takatsugu Ishimoto, Sung Moo Kim, Keon Uk Park, André Luiz Vettore, Byoung Chul Cho, Shenli Zhang, Se Hun Kim, Myung-Ju Ahn, Hwan Jung Yun, Tae Min Kim, Je-Keun Rhee
Publikováno v:
Scientific Reports
Dacomitinib, an irreversible pan-HER inhibitor, had shown modest clinical activity in squamous cell carcinoma of head and neck (SCCHN) patients. Therefore, validated predictive biomarkers are required to identify patients most likely to benefit from
Publikováno v:
Cancer Research. 78:154-154
Background: Classical therapeutic regimens predominantly target proliferating cells, which are unlikely to be cancer stem cells (CSCs). Similarly, new generation therapies, e.g. sorafenib for hepatocellular carcinoma (HCC), do not seem to target CSCs
Autor:
Jong Gwang Kim, Jin Ho Baek, Kyung Hee Lee, Young Rok Do, Keon Uk Park, Min Kyoung Kim, Yee Soo Chae, Hun Mo Ryoo, Jin Young Kim, Sung Hwa Bae, Hong Suk Song
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:527-532
The present study was conducted to evaluate the efficacy and safety of a combination regimen of S-1, paclitaxel plus cisplatin in patients with advanced gastric cancer.Patients with previously untreated metastatic or recurrent, measurable gastric can
Autor:
Dawoom Jeong, Jinyoung Kim, Jehyun Nam, Sang-Woo Kim, Keon Uk Park, Thazin Nwe Aung, Jeong-An Gim
Publikováno v:
Gene. 558(1)
Glucocorticoids (GCs) are chemotherapeutic drugs commonly used to treat hematological malignancies. However, a significant fraction of patients develop resistance to GCs during treatment. A better insight into how GC resistance develops is therefore